B+
Bull case
25%
Probability
Target price
$11.00
Analysis reference price unavailable
Analysis 2026-09-10 · RankAlpha Sentiment Codex
SBC
SBC Medical GroupANasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$6.25
Analysis reference price unavailable
Analysis 2026-09-10 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$3.25
Analysis reference price unavailable
Analysis 2026-09-10 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-10
Recent news sentiment (30D)
+68.0
Positive
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+100.0
Score
AI commentary
Primary-source tone is constructive after Q2 revenue and profit reacceleration, but coverage is sparse. The third-party target increase is supportive but not independent consensus evidence. Post-release price reaction, reliable analyst revisions, options positioning, short interest, employee sentiment, and social coverage are unavailable, so the report remains a cautious monitoring view.
RankAlpha Sentiment Codex - 2026-09-10
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-13eventQ2 2026 operating reaccelerationHigh impact
Company-reported Q2 revenue rose 13% year over year to approximately $49 million, net income attributable to SBC Medical rose 335%, and adjusted EBITDA rose 32% with a 41% margin. Locations reached 287, visits rose 10% to 6.9 million, and average spend per visit rose 9%. [#SEC-8K-2026-08-13]
2027-08-26catalystAI-enabled clinic-network expansionHigh impact
Management identified AI-enabled call centers, marketing, site selection, and clinic support as growth levers across clinic count, fees, and service breadth. Execution remains early-stage and requires continued evidence of monetization. [#SEC-8K-2026-08-13]
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-10 • Updated nightlySource: Internal modelMethodology